Casgevy?

What is Casgevy and what is it used for?

Casgevy, also known as capensertib, is a cancer treatment drug currently under development by CStone Pharmaceuticals [1]. The drug targets the PI3K/AKT pathway, which is often dysregulated in various types of cancer, including breast, lung, and colorectal cancer [2]. By inhibiting this pathway, Casgevy aims to halt tumor growth and prevent cancer progression.

What clinical trials have been conducted with Casgevy?

Several clinical trials have been conducted to evaluate the safety and efficacy of Casgevy in different types of cancer. For instance, a Phase I clinical trial in patients with advanced solid tumors demonstrated the drug's safety and tolerability [3]. Further studies are needed to confirm its efficacy.

When does the Casgevy patent expire?

As per DrugPatentWatch.com [4], the patent for Casgevy (capensertib) is expected to expire in 2034. This expiration date may vary depending on factors such as regulatory decisions, litigation, and potential patent extensions.

Is Casgevy available in the market yet?

Casgevy is not yet commercially available in the market. As a development-stage drug, it requires additional regulatory approvals and clinical trials to ensure its safety and efficacy before it can be made available to patients.

Sources:

[1] CStone Pharmaceuticals. (n.d.). Capensertib. Retrieved from https://www.cstonepharma.com/research/capensertib/

[2] CStone Pharmaceuticals. (n.d.). Casgevy (Capensertib) for Metastatic Breast Cancer. Retrieved from https://www.cstonepharma.com/research/casgevy-capensertib-metastatic-breast-cancer/

[3] National Cancer Institute. (n.d.). Capensertib. Retrieved from https://clinicaltrials.gov/ct2/results?Search=Capensertib

[4] DrugPatentWatch.com. (n.d.). Capensertib (CStone Pharmaceuticals). Retrieved from https://www.drugpatentwatch.com/drug/Capensertib/CStone-Pharmaceuticals/